The largest database of trusted experimental protocols

Anti cd40

Manufactured by R&D Systems
Sourced in United States, United Kingdom

Anti-CD40 is a laboratory reagent that binds to the CD40 protein, which is expressed on the surface of various cell types, including B cells, dendritic cells, and endothelial cells. This product can be used in research applications to study the role of CD40-CD40 ligand interactions in immune function and disease processes.

Automatically generated - may contain errors

21 protocols using anti cd40

1

B Cell Activation and Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
B cells from spleens were purified using MACS isolation (Miltenyi Biotec, Bergisch Gladbach, Germany), and stimulated by anti-IgM F(ab’)2 fragment (anti-IgM, 10 μg/mL) (Jackson ImmunoResearch Laboratories, Philadelphia, PA), anti-IgM added SM (30 μg/mL) (Sigma-Aldrich, St. Louis, MO) or D609 (50 μg/mL) (Sigma-Aldrich, St. Louis, MO) for indicated time. Then the cells were cultured for 24 h and harvested. The isolated B cells were treated with anti-IgM (10 μg/mL) (Jackson ImmunoResearch Laboratories, Philadelphia, PA) and anti-CD40 (100 ng/mL) (R&D systems) for 48 h and then measured by flow cytometry for the differentiation assay.
+ Open protocol
+ Expand
2

Isolation and Stimulation of PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs were isolated from heparinized blood by Ficoll-Hypaque density-gradient centrifugation (Pharmacia Biotech). In some experiments, cells were stimulated with 2.5 μg/ml anti-CD40 (eBioscience) and 20 ng/ml phorbol 12-myristate 13-acetate (PMA; Calbiochem) at 37°C in an atmosphere of 5% CO2 for 48 hours. For stimulation with cytokines, 100 ng/ml recombinant human IL-6 (rhIL-6), 10 ng/ml rhTNF, 10 ng/ml rhIL-1β, or 100 ng/ml rhIL-17A (all from R&D Systems), each in combination with 2.5 μg/ml anti-CD40, was used. To assay for soluble RANKL in culture supernatants, B cells were isolated from PBMCs using CD19 microbeads, and separation was performed with a magnetic-activated cell sorter (Miltenyi Biotec). The cells were then cultured for 48 hours in the presence of anti-CD40 and PMA. Thereafter, the medium was replaced and the cells were returned to culture at 37°C in an atmosphere of 5% CO2 for an additional 5 days. Soluble RANKL was detected by enzyme-linked immunosorbent assay (ELISA; PeproTech), in accordance with the manufacturer’s protocol.
+ Open protocol
+ Expand
3

Human IgG B Cell ELISPOT Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
The ELISPOT assay was performed using a human IgG B cell ELISpot development module (R&D Systems GmbH), and all procedures were performed according to the manufacturer’s instructions. In brief, purified human B cells were stimulated in complete RPMI 1640 with 5 μg/ml anti-IgM, 1 μg/ml anti-CD40, and 100 ng/ml human IL-21 (R&D Systems GmbH). After 4 days, the cells were washed, and 2000 cells were seeded in each well in quintuplicate in a MultiScreen HTS IP filter plate (Millipore) precoated with goat anti-human IgG polyclonal antibody (R&D Systems GmbH). After 16 h, the cells were washed off, and the plate was incubated overnight with biotinylated goat anti-human IgG polyclonal antibody (R&D Systems GmbH) at 4 °C. ELISPOTs were then developed by an ELISpot blue color module (R&D Systems GmbH). The spot number and size were measured by AID EliSpot/FluoroSpot reader systems (Autoimmun Diagnostika GmbH).
+ Open protocol
+ Expand
4

PBMC Isolation, Cell Purification, and Activation Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary peripheral blood mononuclear cells (PBMC) were isolated by Ficoll separation (Ficoll-Paque, GE Healthcare). Normal CD19 + B cells and CD4 + T cells were prepared from human PBMC by B Cell Isolation Kit II and CD4 + T Cell Isolation Kit, respectively (Miltenyi Biotec). The immunopurified cells were confirmed by flow cytometry. DLBCL cell lines SUDHL4, SUDHL6, and SUDHL8 were purchased from DSMZ. Adult T cell leukemia (ATL) patient-derived TL-Om1 cell line was a gift from Dr. K. Sugamura, Tohoku University, Japan. B95.8 EBV-transformed lymphoblastoid cell lines (LCLs) were previously established by infection of lymphocytes from four independent healthy donors with culture supernatants of the virus producer B95.8 line56 (link). All lymphoid cell lines and primary lymphocytes were cultured in RPMI1640 (GIBCO) supplemented with 10% of FBS (GIBCO) and antibiotics (GIBCO). 293T, 293FT, and MDA-MB-231 cells were maintained in DMEM (Nissui, Japan) with 10% of FBS and antibiotics.
B cell activation was performed by anti-IgM (Jackson Immunoresearch Laboratories), BAFF (R&D Systems), anti-CD40 (R&D Systems), and/or IL-4 (R&D Systems). T cell activation was performed by anti-CD3/CD28 antibodies (Miltenyi Biotec).
+ Open protocol
+ Expand
5

Murine Lymphocyte Functional Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Thymocytes were prepared as described earlier (de la Fuente et al., 2006 (link)). Splenic T and B cells were purified by negative selection using kits from Miltenyi Biotec. Thymocytes and purified T cells were cultured in medium alone or in wells coated with 2 µg/ml anti-CD3 monoclonal antibody (clone KT3; Abcam) with or without 2 µg/ml anti-CD28 (clone L293; BD) or 40 ng/ml IL-2 (PeproTech). PMA (Sigma-Aldrich) was used at 50 ng/ml, and ionomycin (Sigma-Aldrich) was used at 0.5 µM. Purified B cells were cultured in medium alone or in the presence of goat F(ab′)2 anti–mouse IgM (Jackson ImmunoResearch Laboratories, Inc.), 2 µg/ml anti-CD40 (R&D Systems), or 10 µg/ml LPS (Sigma-Aldrich). 72 h later, the cells were pulsed with 1 µCi [3H]thymidine and counted.
+ Open protocol
+ Expand
6

Isolation and Stimulation of Human B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human blood B cells were isolated from human peripheral blood mononuclear cells of healthy donors obtained from the Taipei Blood Donation Center and were cultured as described42 (link). The research involving human subjects was approved by the Institutional Review Board of Academia Sinica and informed consent was obtained from all subjects. The experiments were performed in accordance with the approved guidelines. CD27CD19+ and CD19+ B cells were purified by RosetteSep (StemCell). Purified human B cells cultured at a density of 1 × 106 cells/mL were stimulated with IL-21 (100 ng/mL; Invitrogen) and anti-CD40 (1 μg/mL; R&D Systems). NCI-H929 (H929) human multiple myeloma cells and SKW6.4 human lymphoblastoid cells were maintained in RPMI 1640 (Life Technologies) containing 10% FBS (Life Technologies), and 2-ME (50 μM; Life Technologies). FLAG-PRDM1-ERD WI-L2 cells were maintained in phenol red-free RPMI 1640 containing 10% C/D FBS (Life Technologies) and Hygromycin B (0.5 mg/mL; invitrogen). All cells were maintained in medium containing penicillin/streptomycin (100 units/mL; Life Technologies).
+ Open protocol
+ Expand
7

Modulation of mTORC1 in Naive B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
To study mTORC1 activity in naïve B cells, we isolated CD43- resting B cells from 8-10 week-old non-immunized mice using magnetic beads, (Myltenyi, #130-049-801) following manufacturer instructions. 1x106 cells CD43- resting B cells were plated with B cell media (RPMI (US Biological #R8999-04A) +10% dialyzed FBS +55μM β-mercaptoethanol (Gibco, #31350-010) + 10mM HEPES (Lonza #BE17-737E) +100μg/mL penicillin/streptomycin (Gibco, #15070-063) containing no amino acids with or without cytokines (1μg/mL anti-CD40, (R&D Systems, #MAB440) and 25ng/mL mouse Interleukin-4 (R&D Systems, #404-ML)) during 1h. After this time, stimulation with amino acids was performed for 30min and cells where harvested and processed for flow cytometry.
+ Open protocol
+ Expand
8

Plasmablast Differentiation Induction Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human peripheral B cells were treated with KZR-616 as described above for PBMCs and stimulated for 6 days at 0.5x106 cells/mL with 100 ng/mL IL-21 (R&D Systems), 1 µg/mL anti-CD40 (R&D systems), and 5 ug/mL anti-IgM (Jackson ImmunoResearch) to induce plasmablast differentiation. Cells were analyzed by flow cytometry for surface markers including CD19, CD20, and CD38 (BD Biosciences). Supernatants were analyzed for IgG by MSD immunoassay (Meso Scale Diagnostics).
+ Open protocol
+ Expand
9

CD40/CD40L Signaling Modulation in Hepatoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
HepG2.2.15 or HepAD38 cells transfected with CD40 siRNA/siCtrl were stimulated with CD40 ligand (CD40L;1 μg/ml; Cell Signaling Technology, Danvers, MA, USA), neutralizing by preincubation with monoclonal antagonistic antibody against CD40 (anti-CD40; 5 μg/ml; R&D Systems, Minneapolis, MN, USA) or antagonistic antibody against CD40L (anti-CD40L; 0.1 μg/ml; Ancell, Bayport, MN, USA) for 1 h. HepG2.2.15 or HepAD38 cells were seeded in a 6-well plate (5 x 105 cells/well) overnight and then transfected with CD40 plasmid/vector. The inhibitor nifuroxazide (Selleck Chemicals, Houston, TX, USA) at a final concentration of 20 μM was added to the medium for 24 h.
+ Open protocol
+ Expand
10

Culturing Naive B Cells from SLE Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sort purified SLE naive peripheral blood B cells were cultured at a density of 0.5–1 × 105 B cells per well and healthy donor naive peripheral blood B cells were cultured at a density of 1.5 × 105 B cells per well in 96-well round-bottom plates in a final volume of 200 µl complete medium. Culture medium for all experiments was RPMI 1640 (Invitrogen) supplemented with 10% FCS, penicillin-streptomycin (100 units/ml penicillin, 100 mg/ml streptomycin), 2-mercaptoethanol (55 mM), L-glutamine (2 mM), and HEPES (5 mM). At initiation of culture, B cells were stimulated with a combination of IL-21 (40 ng/ml, MedImmune, LLC), anti-CD40 (0.1 µg/ml, goat IgG, R&D Systems), and anti-IgM F(ab’)2 (5.0 µg/ml, Jackson ImmunoResearch Laboratories). The concentration of antibodies used in these experiments was determined based on maximal inhibition achieved in extensive titration studies. B cells were cultured for 5 days prior to examination. The healthy donor naive B cells were also stimulated with CpG-B (1 µg/ml, Invivogen). In order to calculate the total number of CD11chi B cells present after 5 days of culture, the total number of events within the CD11chi gate that was collected in 70 µl of FACS buffer on the BD LSR II flow cytometer (BD Biosciences) was back calculated to the total volume of 100 µl.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!